Literature DB >> 34228545

Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.

Vianney Tuloup1,2, Mathilde France1, Romain Garreau1,2, Nathalie Bleyzac1, Laurent Bourguignon1,2,3, Michel Tod1,2,3, Sylvain Goutelle1,2,3.   

Abstract

Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.

Entities:  

Keywords:  drug-drug interaction; pharmacokinetics; rifabutin; rifampicin

Mesh：

Substances：

Year:  2021        PMID： 34228545      PMCID： PMC8370242          DOI： 10.1128/AAC.01043-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  88 in total

1.  The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.

Authors:  P Barditch-Crovo; C B Trapnell; E Ette; H A Zacur; J Coresh; L E Rocco; C W Hendrix; C Flexner
Journal:  Clin Pharmacol Ther       Date:  1999-04       Impact factor: 6.875

2.  Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.

Authors:  W Ridtitid; M Wongnawa; W Mahatthanatrakul; P Chaipol; M Sunbhanich
Journal:  J Pharm Pharmacol       Date:  2000-10       Impact factor: 3.765

3.  Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women.

Authors:  Hartmut Blode; Susan Zeun; Susanne Parke; Torsten Zimmermann; Beate Rohde; Uwe Mellinger; Michael Kunz
Journal:  Contraception       Date:  2012-03-23       Impact factor: 3.375

4.  The effect of antipyrine and rifampin on the metabolism of diazepam.

Authors:  E E Ohnhaus; N Brockmeyer; P Dylewicz; H Habicht
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

5.  Rifabutin to the Rescue?

Authors:  Henry F Chambers
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

6.  Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.

Authors:  Linh Nguyen; Jaymes Holland; Dale Miles; Caroline Engel; Natacha Benrimoh; Terry O'Reilly; Steven Lacy
Journal:  J Clin Pharmacol       Date:  2015-06-02       Impact factor: 3.126

7.  Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers.

Authors:  Wibool Ridtitid; Malinee Wongnawa; Werawath Mahatthanatrakul; Jarurat Punyo; Methi Sunbhanich
Journal:  Clin Pharmacol Ther       Date:  2002-11       Impact factor: 6.875

8.  Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.

Authors:  Anne-Charlotte Castellan; Michel Tod; François Gueyffier; Mélanie Audars; Fredéric Cambriels; Behrouz Kassaï; Patrice Nony
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

9.  The effect of enzyme induction on the metabolism of disopyramide in man.

Authors:  M L Aitio; L Mansury; E Tala; M Haataja; A Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

Review 10.  Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.

Authors:  James J Natale; Tulla Spinelli; Selma Calcagnile; Corinna Lanzarotti; Giorgia Rossi; David Cox; Kimia Kashef
Journal:  J Oncol Pharm Pract       Date:  2015-05-20       Impact factor: 1.809
View more
  2 in total

Review 1.  Infective Endocarditis in the Elderly: Challenges and Strategies.

Authors:  Carlos Bea; Sara Vela; Sergio García-Blas; Jose-Angel Perez-Rivera; Pablo Díez-Villanueva; Ana Isabel de Gracia; Eladio Fuertes; Maria Rosa Oltra; Ana Ferrer; Andreu Belmonte; Enrique Santas; Mauricio Pellicer; Javier Colomina; Alberto Doménech; Vicente Bodi; Maria José Forner; Francisco Javier Chorro; Clara Bonanad
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-17

2.  A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections.

Authors:  Miranda Monk; Ramy Elshaboury; Alexander Tatara; Sandra Nelson; Monique R Bidell
Journal:  Microbiol Spectr       Date:  2022-05-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.